Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities.
In the company’s own words · 10-K filed Mar 30, 2026 · SEC EDGAR
Business segments
Jun 2026 · $321.4MThe company’s own SEC segment disclosure.
- Related Party License$204.6M64%
- Related Party Service$104.9M33%
- Service$11.9M4%
MeiraGTx Holdings plc (MGTX) reported revenue of $293K in Q1 2026 (quarter ended Mar 31, 2026), down 85% from the same quarter a year earlier. That came with net loss of $46M. For the full year FY2025, revenue was $81M (+145% year on year) and net income −$114M. Its largest product in Jun 2026 was Related Party License at $205M, 64% of the disclosed total, well ahead of Related Party Service at 33%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.